The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca COVID-19 vaccine, updates on the agency’s website showed on Thursday.
Medicines and Healthcare products Regulatory Agency’s (MHRA) decision comes after the European medicines agency added GBS as a possible side-effect last month.
What is Guillain-Barré syndrome?
Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system—the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently. Fortunately, most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness.
Guillain-Barré syndrome can affect anyone. It can strike at any age (although it is more frequent in adults and older people) and both sexes are equally prone to the disorder. GBS is estimated to affect about one person in 100,000 each year.
The post UK adds GBS as rare side-effect of AstraZeneca vaccine appeared first on ARY NEWS.
from Health – ARY NEWS https://ift.tt/3jniIBo
0 Comments